How to Translate Media Results Into a Commercial Investment Case

Build the case in seven lines

1. Decision requested and deadline.
2. Population, period, spend, and media treatment.
3. Measured result with method and uncertainty.
4. What can and cannot be inferred causally.
5. Commercial range and break-even threshold.
6. Operational capacity and scale risk.
7. Recommendation, trigger, owner, and next read.

Keep evidence classes separate

Model the next dollar

Historical average cost can hide saturation. Estimate the reach, price, frequency, audience composition, and outcome expected from the proposed increment. Show downside, base, and upside ranges and the assumptions that move them.

Hypothetical case

A controlled study estimates 250 incremental prescriptions, with an interval of 80 to 420, on $500,000 spend. Finance's illustrative break-even is 180. The point estimate supports investment, but the interval includes a downside below break-even. A staged $200,000 expansion with a replication condition may dominate a full rollout. All figures are hypothetical.

Include the counter-case

State what would make the recommendation wrong: weaker transferability, higher clearing cost, less eligible reach, lower treatment persistence, supply constraints, or concurrent commercial changes. Assign monitoring indicators.

Avoid false ROI

Do not multiply attributed prescriptions by product value and call the result return on media. Use incremental outcomes where credible, include full relevant costs, and let finance own contribution assumptions. Preserve confidentiality and comply with company policy.

How finance will test the case

Expect finance partners to probe four areas. Prepare answers before the meeting.

Transferability. Will the effect measured in one flight, audience, or season hold at a larger scale or in a different period? Show what changes between the tested and proposed conditions.

Marginal cost. Will the next dollar buy the same reach at the same price? Supply constraints often raise costs as spend grows. Show an estimate of the price curve.

Contribution assumptions. What is an incremental prescription worth, and over what time horizon? Let finance own this number. Media teams should not supply product economics.

Downside protection. What happens if the result does not replicate? A staged plan with a clear stop rule is easier to approve than an all-or-nothing request.

A useful exercise is to ask a colleague from analytics or finance to argue against the recommendation before you present it. Their objections become the counter-case section. See how to forecast incremental prescriptions and statistical significance vs. commercial importance for the supporting methods.

Practical takeaway

The commercial case is a decision memo, not a performance deck. The next step is to replace point ROI with an evidence-labeled range, break-even line, and staged funding option.

Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.